Natriumvalproaat Seacross (Sodium Valproate)

Sodium valproate increases the level of the inhibitory neurotransmitter GABA by blocking its breakdown, and it also inhibits voltage‑gated sodium channels. This dual action stabilises neuronal membranes, reduces excessive neuronal firing, and helps control seizure activity and mood fluctuations.

The appropriate dose of Natriumvalproaat Seacross is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and response to therapy. Dosage adjustments are made according to therapeutic drug monitoring and individual tolerability.

Sodium valproate is classified as pregnancy Category X because it is known to cause serious birth defects and developmental disorders. It is contraindicated in pregnancy and should not be used by breastfeeding mothers unless the benefits clearly outweigh the risks and under specialist supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Compared with other anticonvulsants, sodium valproate offers broad‑spectrum seizure control and mood‑stabilising effects, but it carries a higher risk of hepatic and hematologic toxicity. Clinicians often weigh these risks against benefits when choosing between valproate, carbamazepine, lamotrigine, or newer agents.

The injectable solution should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability and ensure proper temperature control during transport and storage.

Natriumvalproaat Seacross is administered intravenously by a healthcare professional. The infusion rate and volume are determined by the prescriber, and the medication should be given under appropriate clinical monitoring to observe for efficacy and potential adverse reactions.

The most serious risks include severe liver injury, acute pancreatitis, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and significant hematologic abnormalities like thrombocytopenia. Patients should be monitored regularly for signs of these conditions, especially during the initial months of therapy.

Natriumvalproaat Seacross is contraindicated in pregnant women, patients with known hypersensitivity to valproate, individuals with existing liver disease, and those with urea cycle disorders. It should also be used with caution in patients with a history of pancreatitis or severe hematologic disorders.